
Translating Science into Medicine

Oscotec 3.5

Translating Science into Medicine**



Where We Are




Phase 1: Start up

Phase 2: Grow up

Phase 3: Scale up


AML = Acute Myelogenous Leukemia; RA = Rheumatoid Arthritis; ITP = Immune Thrombocytopenia Purpura; AD = Alzheimer's Disease

Growth Strategy 2021



- Revenue stream from lazertinib
- Build upon success of the current clinical pipeline
- Pipeline enrichment via open innovation
- Sustained growth with maturing internal programs and platform technologies

R&D Pipeline 2025



Legacy Programs; Lazer/Cevi/Denfi

Lazertinib (EGFR inhibitor)

- Global approval/launch in 1L NSCLC as Rybrevant combination
- Compelling improvement in PFS and OS vs competition
- Subcutaneous Rybrevant to boost sales significantly

Cevidoplenib (SKI-O-703; SYK inhibitor)

- Demonstrated efficacy and safety in ITP P2; excellent GI tolerability
- P3-ready in 2L ITP (ODD); IIT in 1L ITP to start
- Opportunities of indication expansion (RA subset, GvHD, AMR, etc)
- Extra 20 years of IP protection (crystal form)

Denfivontinib (SKI-G-801; FLT3/AXL inhibitor)

- Demonstrated efficacy and safety in FLT3-mut AML patients
- Confirmed safety and PK exposure as an oral agent
- Further internal development efforts postponed for strategic reasons

NSCLC = Non-Small Cell Lung Cancer; ITP = Immune Thrombopenia Purpura; GI = GastroIntestinal; ODD = Orphan Drug Designation; RA = Rheumatoid Arthritis; GvHD = Graft vs Host Disease; AMR = Antibody-Mediated Rejection; IP = Intellectual Property; AML = Acute Myelogenous Leukemia

Stepstone Programs

ADEL-Y01 (anti-Tau AcK280 antibody)

- Under co-development agreement with Adel Pharma
- P1 study ongoing in the US (AD-MCI and mild AD)
 - Part I in HV; SAD cohort 3 (20 mg); cohort 4 to start (50 mg)
 - Part II in patients; MAD cohort 1 to start (7.5 mg)
- Best-in-class anti-MTBR tau antibody targeting pathogenic tau
- Surging interest in anti-MTBR tau after P2a POC by bepranemab (UCB)


OCT-598 (EP2/4 dual antagonist)

- Licensed from Kanaph Therapeutics
- IND to be filed in 2Q2025 (FDA) and 3Q2025 (MFDS); FIH in 4Q
- SOC combination in multiple tumor types aiming at improved PFS
- Trailblazer program for Oscotec's CTR-targeting approach

NSCLC = Non-Small Cell Lung Cancer; ITP = Immune Thrombopenia Purpura; GI = GastroIntestinal; ODD = Orphan Drug Designation; RA = Rheumatoid Arthritis; GvHD = Graft vs Host Disease; AMR = Antibody-Mediated Rejection; IP = Intellectual Property; AML = Acute Myelogenous Leukemia

Next-Generation Oncology

- Conventional anti-tumor therapy has solely focused on cancer cell killing
- Resistance/relapse is the most critical unmet need in oncology; "What doesn't kill you makes you stronger"
- Extensive studies have pointed to wildly diverse mechanisms of resistance development; dormancy, mutation, EMT, stemness, etc
- Ploidy cycle encompasses all these phenomena and provides a unified, holistic framework of resistance development
- In fact, ploidy cycle is the ultimate cellular stress response and the primordial driver of speciation and evolution in Nature
- Prudent targeting the ploidy cycle concurrently with SOC treatment will prevent cancer cells from adapting to the therapeutic pressure, negate resistance development, and prolong PFS, potentially leading to cancer 'cure'




Erenpreisa et al., Seminars in Cancer Biol 2020


CTR = Cancer Therapy Resistance; EMT = Epithelial-Mesenchymal Transision; SOC = Standard Of Care; PFS = Progression-Free Survival


Sneak Preview; ONC1


 PDAC cells acquire resistance to gemcitabine via ploidy cycle












2N 4N

Polyploidy



Genosco Pipeline

GNS-3545 (ROCK2 inhibitor)

- IND in IPF to be filed in 2Q2025
- Highly potent and selective Rock2 inhibitor prodrug
- Belumosudil (Kadmon/Sanofi) approved for cGvHD

• GNS-3288/5705 (ROCK2 inhibitor)

- Potent, selective, and brain-penetrant Rock2 inhibitors
- Rock2 highly activated in CCM
- Ovid/Graviton and Neurelis in clinical phase


GNS-4699 (GSPT1 degrader)

- Exquisite potency vs competitors (BMS, Monte Rosa, etc)
- To target MYC-driven tumors such as SCC or HCC
- To be also developed as a DAC payload



IPF = Idiopathic Pulmonary Fibrosis; cGvHD = chronic Graft versus Host Disease; BBB = Blood Brain Barrier; CCM = Cerebral Cavernous Malformation; SCC = Squamous Cell Carcinoma; HCC = HepatoCellular Carcinoma; DAC = Degrader-Antibody Conjugate

One Root, Two Companies



NSCLC = Non-Small Cell Lung Cancer; ITP= Immune Thrompcytopenia Purpura; I&I = Immune and Inflammatory diseases; AML = Acute Myelogenous Leukemia; CTR* = Cancer Therapy Resistance; IPF = Idiopathic Pulmonary Fibrosis; CCM = Cerebral Cavernous Malformation; HCC = HepatoCellular Carcinoma; SCC = Squamous Cell Carcinoma

Oscotec Positioning

- De-risked targets (fast-follower)
- Differentiation challenges → TPP!
- High competition (China!)



Pipeline

- Novel, high-risk targets (first-mover)
- Scientific challenges → POC!
- Early licensing opportunities



Low (BiC)

Target Novelty

High (FiC)

- Validation challenges; boom or bust
- Incremental improvement
- Early collaboration opportunities



Platform

Too risky until platform matures



Oscotec Vision

"LEADING INNOVATION ENGINE that translates the SCIENCE OF LIFE into FIRST-IN-CLASS medicine for unmet clinical needs"